Genetics

This scientific blog post examines a Mendelian randomization study by Almramhi and colleagues that investigates whether plasma lipid levels and statin-related biological pathways influence multiple sclerosis risk and severity. The article highlights evidence that genetically predicted RAC2 expression, part of a cholesterol-independent Rho GTPase pathway, may reduce MS risk, while genetically higher HDL cholesterol may increase susceptibility to MS. In contrast, LDL cholesterol, triglycerides, and cholesterol biosynthesis pathways showed no clear causal relationship with MS risk or severity. The post discusses how these findings refine our understanding of statin biology in neuroimmunology and suggest that potential statin effects in MS may depend more on immune-modulatory mechanisms than on cholesterol lowering alone.